Literature DB >> 27169415

Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls.

Philip Brenner1, Ellenor Mittendorfer-Rutz2, Jussi Jokinen3,4, Kristina Alexanderson2, Jan Hillert5, Petter Tinghög2,6.   

Abstract

BACKGROUND: Many multiple sclerosis (MS) patients of working ages have psychiatric comorbidity, and 60 % are on disability pension (DP). It is unknown how DP is associated with MS patients' mental health. The objective of this study was to investigate the association between prescriptions of psychiatric medication and time before and after receiving full-time DP in MS patients compared with matched controls.
METHODS: Nationwide Swedish registers were used to identify 3836 MS patients who were granted DP in 2000-2012 and 19,180 DP controls matched on socio-demographic variables by propensity scores. Patients and controls were organized in groups by year granted DP. Adjusted odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated for being prescribed selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, or sleeping agents in 2006.
RESULTS: Both patients and controls, who were not yet on DP in the study year of 2006, had lower OR compared with those who were granted DP in the same year. The OR increased when being closer to DP. MS patients, who had been granted DP 5-6 years earlier, had a higher risk for prescription of benzodiazepines (OR 1.72; 95 % CI 1.16-2.57) than controls (OR 1.14; 95 % CI 1.14-1.18). These patients also had a higher risk for SSRI prescription when compared directly with controls (OR 1.76; 95 % CI 1.44-2.15).
CONCLUSIONS: MS patients have substantially higher odds ratios for being prescribed psychiatric drugs after DP than other disability pensioners. Further research on the association of DP with the mental health of MS patients is warranted.

Entities:  

Keywords:  Benzodiazepines; Depression; Disability pension; Epidemiology; Hypnotics and sedatives; Multiple sclerosis; Serotonin uptake inhibitors; Sick leave

Mesh:

Substances:

Year:  2016        PMID: 27169415     DOI: 10.1007/s00127-016-1234-3

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  33 in total

1.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

Authors:  Peter C Austin; Paul Grootendorst; Geoffrey M Anderson
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

Review 2.  Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review.

Authors:  H M B Lunde; B Bjorvatn; K-M Myhr; L Bø
Journal:  Acta Neurol Scand Suppl       Date:  2013

3.  Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern.

Authors:  D C Kroencke; S G Lynch; D R Denney
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

4.  The mental health of early retirees-- national interview survey in Britain.

Authors:  Julian W Buxton; Nicola Singleton; David Melzer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

5.  Suicide risk in relation to socioeconomic, demographic, psychiatric, and familial factors: a national register-based study of all suicides in Denmark, 1981-1997.

Authors:  Ping Qin; Esben Agerbo; Preben Bo Mortensen
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

6.  Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

Authors:  P B Andersson; E Waubant; L Gee; D E Goodkin
Journal:  Arch Neurol       Date:  1999-09

7.  The natural history of secondary progressive multiple sclerosis.

Authors:  Marcus Koch; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

Review 8.  Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.

Authors:  Ralf Gold; Celia Oreja-Guevara
Journal:  Expert Rev Neurother       Date:  2013-12       Impact factor: 4.618

9.  Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort.

Authors:  Viktoria Johansson; Cecilia Lundholm; Jan Hillert; Thomas Masterman; Paul Lichtenstein; Mikael Landén; Christina M Hultman
Journal:  Mult Scler       Date:  2014-07-10       Impact factor: 6.312

10.  Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis.

Authors:  F Patti; C Pozzilli; E Montanari; A Pappalardo; L Piazza; A Levi; E Onesti; I Pesci
Journal:  Mult Scler       Date:  2007-02-16       Impact factor: 6.312

View more
  1 in total

1.  Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein
Journal:  Front Neurol       Date:  2022-04-14       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.